Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aventis Lovenox Patent Defense: Re-Issuance Higher Priority Than Stay

Executive Summary

Aventis' Lovenox generic defense remains centered on the re-issuance of an enoxaparin patent as the company defends the original version against potential generic competition

You may also be interested in...



Lovenox Patent Re-Issuance Denied: Aventis To Submit Response Shortly

Aventis plans to submit additional information on Lovenox to the Patent & Trademark Office after the agency denied re-issuance of a patent central to the company's defense against enoxaparin generics

Lovenox Patent Re-Issuance Denied: Aventis To Submit Response Shortly

Aventis plans to submit additional information on Lovenox to the Patent & Trademark Office after the agency denied re-issuance of a patent central to the company's defense against enoxaparin generics

Sanofi/Aventis Merger Would Create Top 10 U.S. Pharma Company

A Sanofi/Aventis merger combination would break Sanofi into the top 10 ranking of U.S. pharmaceutical companies

Related Content

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel